Physician profile
Patrick F Hammen
NPI 1164461505
$10,084.75
in general payments reported to CMS, 2019-2025
12 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $7,075 · 2021: $1,078 · 2022: $71.58 · 2023: $286 · 2024: $220 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,130.34 | 2019-2023 | Da Vinci Surgical System |
| Medtronic, INC. | $242.58 | 2023-2024 | Manoscan, Interstim |
| Davol INC. | $232.72 | 2019-2025 | Arista, Phasix Mesh |
| Thd America, INC. | $172.97 | 2024 | |
| Dilon Technologies, INC. | $144.58 | 2025 | Hemoblast Bellows |
| Boston Scientific Corporation | $49.75 | 2019-2025 | Axonics |
| Ethicon US, LLC | $24.99 | 2023 | Echelon Circular, Echelon Flex |
| Prescient Surgical | $22.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.28 | 2019 | |
| Incyte Corporation | $17.22 | 2020 | |
| Braintree Laboratories, INC. | $15.10 | 2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hammen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.